This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Maslowski, L. Articles by Wysokinski, W. E Search for Related Content PubMed PubMed Citation Articles by Maslowski, L. Articles by Wysokinski, W. E Social Bookmarking                   What's this?

Antiphospholipid antibodies in thromboangiitis obliterans

Department and Clinic of Angiology, University Medical School of Wroclaw, Poland

Robert McBane

Division of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA

Pawel Alexewicz

Department and Clinic of Angiology, University Medical School of Wroclaw, Poland

Waldemar E Wysokinski

Division of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA, wysokinski.waldemar{at}mayo.edu

Thromboangiitis obliterans (TAO) and antiphospholipid syndrome (APS) share the clinical characteristics of arterial thrombosis and recurrent thrombophlebitis. Although the association of anticardiolipin antibodies (aCLa) and TAO has been previously recognized, the prevalence and the clinical impact of this association remains unclear.

aCLa were measured by double ELISA in patients with TAO (n=47), premature atherosclerosis (pASO) (n=48) and otherwise healthy individuals (n=48). Antibody status was then compared to clinical presentation and outcomes in patients meeting the diagnostic criteria for TAO. The prevalence of aCLa was significantly higher in patients with TAO (36%) compared to either pASO (8%; p=0.01) or healthy individuals (2%; p,0.001). Patients with TAO and a high antibody titer tended to be younger and suffer a significantly higher rate of major amputations compared to those without the antibody (100% versus 17%; p=0.003). Clinical features of TAO not significantly altered by the presence of aCLa included upper limb involvement, digital necrosis, superficial thrombophlebitis (or deep venous thrombosis). Protein C, protein S, and anti-thrombin III were normal in all individuals.

TAO is associated with an increased prevalence of aCLa. The presence of a high antibody titer in these patients is associated with increased morbidity, including major limb amputation. In patients meeting the diagnostic criteria for TAO, screening for aCLa should be considered. Although attractive, the efficacy of chronic anticoagulation in this setting remains to be proven.

Key Words: anticardiolipin antibodies • premature atherosclerosis • thromboangiitis obliterans • thrombosis

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				K. I. Paraskevas, C. D. Liapis, D. D. Briana, and D. P. Mikhailidis Thromboangiitis Obliterans (Buerger's Disease): Searching for a Therapeutic Strategy Angiology, February 1, 2007; 58(1): 75 - 84. [Abstract] [PDF]

				X. Puechal and J.-N. Fiessinger Thromboangiitis obliterans or Buerger's disease: challenges for the rheumatologist Rheumatology, February 1, 2007; 46(2): 192 - 199. [Abstract] [Full Text] [PDF]